Azure Holding Group Corp (AZRH): Cohen says he’s not diluting the float a...

Cohen says he’s not diluting the float and

PennyStaIker · 2024-10-05T12:31:00.9470000Z

Cohen says he’s not diluting the float and is looking to uplist in new video: https://www.instagram.com/reel/DAu67wGO982/?igsh=MWZ5aW40dTk3MXQ5cg%3D%3D

Play Episode

4min

Proactive - Interviews for investors

Rome Resources achieves major milestone with copper mineralisation at Mont Agoma

Rome Resources Plc (AIM:RMR) CEO Paul Barrett talked with Proactive's Stephen Gunnion about the latest assay results from drilling at Mont Agoma in the DRC. The company has identified a significant copper zone with potential for tin mineralisation at depth. Barrett highlighted that Hole 18 intersected a 250-meter copper zone, while Hole 24, drilled beneath a previous hole, revealed visible tin mineralisation, supporting their geological model. The CEO explained that all four drill rigs are currently focused on Mont Agoma, with deeper holes underway to further define the mineralisation. He noted that the system appears wider than initially expected, which is an encouraging development. Assays for Hole 24 are still pending, but early visual indications suggest strong tin content. Barrett also provided an update on the company's resource estimates, stating that the maiden inferred mineral resource for Kalayi should be available by the end of March, with Mont Agoma's estimate following within a couple of months. He emphasised the complexity of the Mont Agoma deposit due to its polymetallic nature but reassured investors that progress is steady. Stay tuned for more updates on Rome Resources' drilling program. Don't forget to like this video, subscribe to Proactive's YouTube channel, and turn on notifications for the latest updates. #RomeResources #Copper #Tin #Mining #DRC #DrillingResults #MineralExploration #Investing #JuniorMining #ResourceEstimate

Proactive - Interviews for investors

Lisata Therapeutics expands drug discovery with GATC AI collaboration

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo talked with Proactive about the company’s strategic collaboration with GATC Health, a leader in artificial intelligence-driven drug discovery. Mazzo explained that GATC’s technology, which is recognized by Lloyd’s of London for clinical trial risk assessment, will be used to analyze Lisata’s lead candidate, certepetide, and identify potential new drug combinations. Mazzo highlighted that this collaboration will optimize Lisata’s ongoing cancer research, including trials in pancreatic ductal adenocarcinoma, cholangiocarcinoma, and other cancers. He noted that GATC’s AI technology can perform billions of simulations rapidly, potentially reducing the cost and risk of drug development. Discussing Lisata’s 2025 outlook, Mazzo described it as a "data-rich year," with upcoming results from the ASCEND trial and other studies. He emphasized the potential for certepetide in combination with immunotherapy and the company’s ongoing discussions with regulatory agencies and potential partners. To watch more interviews like this, visit Proactive’s YouTube channel. Don't forget to like this video, subscribe, and enable notifications for future updates. #LisataTherapeutics #Biotech #CancerResearch #AIinHealthcare #DrugDevelopment #ClinicalTrials #GATCHealth #Pharma #Oncology #Investing

Proactive - Interviews for investors

Sprott & HANetf launch physical uranium ETC targeting European investors

Sprott Asset Management CEO John Ciampaglia talked with Proactive's Stephen Gunnion about the launch of the Sprott Physical Uranium ETC (ISE:SPUT) in partnership with HANetf. Ciampaglia explained that this new product is an extension of the Sprott Physical Uranium Trust, a popular investment vehicle that trades on the Toronto Stock Exchange. According to Ciampaglia, the new ETC aims to address a key gap in the market by providing non-institutional European investors with easier access to uranium investment. He noted that uranium plays a crucial role in the global energy transition, as nuclear energy is gaining renewed interest due to its ability to provide baseload power, energy security, and zero greenhouse gas emissions. Ciampaglia also discussed the differences between investing in physical uranium versus uranium mining stocks. He emphasised that physical uranium is often considered a cornerstone investment, while uranium miners offer greater upside potential and operating leverage. Many investors, he said, choose to balance both approaches in their portfolios. Watch the full interview for more insights into uranium investing and the future of nuclear energy. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for updates. #Sprott #Uranium #NuclearEnergy #Investing #HANetf #EnergySecurity #ETC #MiningStocks #PhysicalUranium #ProactiveInvestors

Proactive - Interviews for investors

Daniel Tillett on Race Oncology’s drug advancements

Race Oncology Ltd CEO and managing director Daniel Tillett talked with Proactive about the company’s development of a reformulated cancer drug aimed at improving chemotherapy treatment. Tillett discussed the challenges of chemotherapy, including severe side effects, and how Race Oncology is working to minimise these risks while enhancing treatment effectiveness. He explained that the company has taken an older, previously approved drug and developed a new formulation that improves its delivery while protecting patients from heart-related side effects. This new approach, which involves combining the reformulated drug with anthracyclines, aims to enhance cancer treatment while reducing long-term health risks for patients. Tillett highlighted the significant market potential for the company’s drug, given that anthracyclines remain a cornerstone of cancer treatment. The company is now advancing into clinical trials, with results expected to provide key insights into the drug’s effectiveness in humans. Watch the full interview to learn more about Race Oncology’s latest advancements. Don’t forget to like this video, subscribe to Proactive’s YouTube channel, and turn on notifications for more updates on cutting-edge biotech developments. #RaceOncology #CancerTreatment #Biotech #Chemotherapy #Pharmaceuticals #DrugDevelopment #ClinicalTrials #OncologyResearch #Investing #CancerResearch #Cardioprotection

Followers	15
Posts	452
Boards Moderated	0
Alias Born	02/14/2021

Volume:	99,512
Day Range:	0.143 - 0.177
Bid:	0.143
Ask:	0.1651
Last Trade Time:	3:44:31 PM EDT
Total Trades:	25

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

AZRH Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free